John Boghossian

John is CEO and Director at Kanna Health.

He is passionate about life sciences entrepreneurship around natural products. He was previously CEO at Quercis Pharma, a Swiss-based clinical-stage biotech focused on the development of novel antithrombotic and antiviral therapies. Their lead product Kinisoquin includes a bioavailable prodrug of the naturally-occurring flavonoid quercetin.

Prior to this, John was the first full-time employee at COMPASS Pathways (Nasdaq ticker CMPS), a UK-based clinical-stage biotech company focused on the development of psilocybin, a naturally-occurring tryptamine, for psychiatric and mood disorders. He was fortunate to witness and participate to the company’s growth from Seed to IPO. In his last role as VP of Operations, he led overall operations and was heavily involved in clinical operations around the company’s multi-center Phase 2b study as well as pre-commercial Market Access activities. He also co-led private fundraising activities, raising USD 120 million in private rounds followed by a USD 150 million IPO on the NASDAQ.

Prior to working in biotech, John started his career in the Life Sciences and Energy practices at the Boston Consulting Group (BCG) in Western Europe and the USA. He holds a Master of Business Administration from the Harvard Business School (HBS), a Master’s degree in engineering from Cambridge University, and Bachelor’s degrees in Mechanical Engineering and Economics from MIT.

John grew up between Belgium, Lebanon and the USA.